文献速递浆细胞疾病

综合CRISPR-Cas9筛选揭示多发性骨髓瘤药物反应性的遗传决定因素

Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma.
PubMed 文献 · Blood Adv · 2021-01-01

该研究对16例多发性骨髓瘤患者的纵向样本进行全外显子测序,并结合针对来那度胺、硼替佐米、地塞米松和美法仑的CRISPR-Cas9耐药筛选,系统评估复发特异性基因突变与药物敏感性的因果关系。研究将15个复发特异性突变与耐药功能关联,并发现DNA损伤修复通路基因失活增强化疗敏感性,耐药模式具有高度药物特异性。

要点

  • 纵向WES揭示每例患者新获得或演化的突变中位9个(范围1-55)。
  • CRISPR筛选将15个复发特异性突变与耐药功能关联。
  • DNA损伤修复基因失活增强细胞毒化疗敏感性。

核心结论

  • 复发特异性基因突变与多发性骨髓瘤药物敏感性存在功能关联,耐药模式高度药物特异性。

研究设计与样本

  • 结合16例多发性骨髓瘤患者纵向样本的全外显子测序与针对来那度胺、硼替佐米、地塞米松和美法仑的CRISPR-Cas9耐药筛选。

主要发现

  • 纵向样本WES显示每例患者新获得或从小亚克隆演化的突变中位9个(范围1-55),包括TP53、DNAH5和WSCD2的反复突变。
  • 针对170个复发特异性突变的聚焦CRISPR-Cas9耐药筛选将其中15个与耐药功能关联。
  • 来那度胺耐药关联cereblon E3泛素连接酶复合体成员,地塞米松关联PCDHA5和ANKMY2,硼替佐米关联RB1和CDK2NC,美法仑关联TP53。
  • ATM、FANCA、RAD54B和BRCC3等DNA损伤修复通路基因失活增强对细胞毒化疗的敏感性。
  • 耐药模式高度药物特异性且重叠低,并与患者治疗依赖的克隆演化高度相关。

临床怎么用

  • 特定遗传改变与药物敏感性的功能关联有助于未来多发性骨髓瘤的个体化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The introduction of new drugs in the past years has substantially improved outcome in multiple myeloma (MM). However, the majority of patients eventually relapse and become resistant to one or multiple drugs. While the genetic landscape of relapsed/ resistant multiple myeloma has been elucidated, the causal relationship between relapse-specific gene mutations and the sensitivity to a given drug in MM has not systematically been evaluated. To determine the functional impact of gene mutations, we performed combined whole-exome sequencing (WES) of longitudinal patient samples with CRISPR-Cas9 drug resistance screens for lenalidomide, bortezomib, dexamethasone, and melphalan. WES of longitudinal samples from 16 MM patients identified a large number of mutations in each patient that were newly acquired or evolved from a small subclone (median 9, range 1-55), including recurrent mutations in TP53, DNAH5, and WSCD2. Focused CRISPR-Cas9 resistance screens against 170 relapse-specific mutations functionally linked 15 of them to drug resistance. These included cereblon E3 ligase complex members for lenalidomide, structural genes PCDHA5 and ANKMY2 for dexamethasone, RB1 and CDK2NC for bortezomib, and TP53 for melphalan. In contrast, inactivation of genes involved in the DNA damage repair pathway, including ATM, FANCA, RAD54B, and BRCC3, enhanced susceptibility to cytotoxic chemotherapy. Resistance patterns were highly drug specific with low overlap and highly correlated with the treatment-dependent clonal evolution in patients. The functional association of specific genetic alterations with drug sensitivity will help to personalize treatment of MM in the future.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bohl SR, Schmalbrock LK, Bauhuf I, et al. Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma. Blood Adv. 2021. PMID: 33950175. doi:10.1182/bloodadvances.2020003541

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。